CT-P6对比参照曲妥珠单抗治疗HER2阳性乳腺癌:随机双盲阳性对照3期等效性试验
该随机双盲3期等效性试验纳入549例HER2阳性早期乳腺癌患者,比较新辅助CT-P6与参照曲妥珠单抗的疗效。CT-P6组病理完全缓解率为46.8%,参照曲妥珠单抗组为50.4%,率差的95%CI在预设等效界值内,不良事件相似。
要点
- CT-P6组病理完全缓解46.8%,参照曲妥珠单抗组50.4%,率差95%CI在等效界值内。
- CT-P6组严重治疗中出现的不良事件7%,参照曲妥珠单抗组8%。
- 3级及以上治疗相关不良事件CT-P6组6%,参照曲妥珠单抗组8%。
核心结论
- CT-P6与参照曲妥珠单抗疗效等效,不良事件相似。
- 曲妥珠单抗生物类似药的可及性可能增加HER2阳性早期乳腺癌患者接受靶向治疗的机会。
研究设计与样本
- 随机、双盲、阳性对照、3期等效性试验,纳入549例I-IIIa期可手术HER2阳性乳腺癌女性患者。
- 患者按1:1随机分配接受新辅助CT-P6或参照曲妥珠单抗静脉给药,联合多西他赛和FEC方案化疗。
- 主要疗效终点为病理完全缓解,在符合方案人群中分析,等效界值为-0.15至0.15。
主要发现
- CT-P6组248例中116例(46.8%;95%CI 40.4-53.2)达到病理完全缓解,参照曲妥珠单抗组256例中129例(50.4%;95%CI 44.1-56.7)。
- 估计治疗结局差异为-0.04%(95%CI -0.12至0.05),95%CI在等效界值内。
- CT-P6组271例中19例(7%)报告严重治疗中出现的不良事件,参照曲妥珠单抗组278例中22例(8%)。
- CT-P6组271例中17例(6%)发生3级及以上治疗相关不良事件,参照曲妥珠单抗组278例中23例(8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. METHODS: In this randomised, double-blind, active-controlled, phase 3 equivalence trial, we recruited women aged 18 years or older with stage I-IIIa operable HER2-positive breast cancer from 112 centres in 23 countries. Inclusion criteria were an Eastern Cooperative Oncology Group performance status score of 0 or 1; a normal left ventricular ejection fraction of at least 55%; adequate bone marrow, hepatic, and renal function; at least one measureable lesion; and known oestrogen and progesterone receptor status. Exclusion criteria included bilateral breast cancer, previous breast cancer treatment, previous anthracycline treatment, and pregnancy or lactation. We randomly allocated patients 1:1 to receive neoadjuvant CT-P6 or reference trastuzumab intravenously (eight cycles, each lasting 3 weeks, for 24 weeks; 8 mg/kg on day 1 of cycle 1 and 6 mg/kg on day 1 of cycles 2-8) in conjunction with neoadjuvant docetaxel (75 mg/m2 on day 1 of cycles 1-4) and FEC (fluorouracil [500 mg/m2], epirubicin [75 mg/m2], and cyclophosphamide [500 mg/m2]; day 1 of cycles 5-8) therapy. We stratified randomisation by clinical stage, receptor status, and country and used permuted blocks. We did surgery within 3-6 weeks of the final neoadjuvant study drug dose, followed by an adjuvant treatment period of up to 1 year. We monitored long-term safety and efficacy for 3 years after the last patient was enrolled. Participants and investigators were masked to treatment until study completion. The primary efficacy endpoint, analysed in the per-protocol population, was pathological complete response, assessed via specimens obtained during surgery, analysed by masked central review of local histopathology reports. The equivalence margin was -0·15 to 0·15. This trial is registered with ClinicalTrials.gov, number NCT02162667, and is ongoing, but no longer recruiting. FINDINGS: Between Aug 7, 2014, and May 6, 2016, we randomly allocated 549 patients (271 [49%] to CT-P6 vs 278 [51%] to reference trastuzumab). A similar proportion of patients achieved pathological complete response with CT-P6 (116 [46·8%; 95% CI 40·4-53·2] of 248 patients) and reference trastuzumab (129 [50·4%; 44·1-56·7] of 256 patients). The 95% CI of the estimated treatment outcome difference (-0·04% [95% CI -0·12 to 0·05]) was within the equivalence margin. 19 (7%) of 271 patients in the CT-P6 group reported serious treatment-emergent adverse events versus 22 (8%) of 278 in the reference trastuzumab group; frequent (occurring in more than one patient) serious adverse events were febrile neutropenia (four [1%] vs one [<1%]) and neutropenia (one [<1%] vs two [1%]). Grade 3 or worse treatment-related adverse events occurred in 17 (6%) of 271 patients in the CT-P6 group versus 23 (8%) of 278 in the reference trastuzumab group; the most frequently reported adverse event was neutropenia in ten (4%) versus 14 (5%). INTERPRETATION: CT-P6 showed equivalent efficacy to reference trastuzumab and adverse events were similar. Availability of trastuzumab biosimilars could increase access to this targeted therapy for HER2-positive early-stage cancer. FUNDING: Celltrion Inc.
引用
- Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017. PMID: 28592386. doi:10.1016/S1470-2045(17)30434-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。